Skip to main content

Table 1 Baseline characteristics of participants (N = 210)

From: Association between HIV duration and symptom distress among middle-aged and elderly people with HIV-infected in China: a cross-sectional study

Variables

HIV duration

Total

(n = 210)

 < 1 years

(n = 28)

1–5 years

(n = 85)

6–10 years

(n = 51)

 > 10 years

(n = 46)

p-value

Age, Mean ± SD

50.8 ± 8.0

52.5 ± 8.8

49.7 ± 7.7

51.0 ± 6.9

51.6 ± 9.1

0.330

Gender, n (%)

     

0.581

 female

61 (29.0)

7 (25.0)

24 (28.2)

13 (25.5)

17 (37.0)

 

 male

149 (71.0)

21 (75.0)

61 (71.8)

38 (74.5)

29 (63.0)

 

Race, n (%)

     

0.078

 Minority

22 (10.5)

0 (0)

10 (11.8)

4 (7.8)

8 (17.4)

 

 Han

188 (89.5)

28 (100)

75 (88.2)

47 (92.2)

38 (82.6)

 

Education, n (%)

     

0.005

 Middle school or below

110 (52.4)

20 (71.4)

46 (54.1)

18 (35.3)

26 (56.5)

 

 High school or equivalent

51 (24.3)

2 (7.1)

21 (24.7)

22 (43.1)

6 (13.0)

 

 Junior college or Undergraduate and above

49(23.4)

6 (21.4)

18 (21.2)

11 (21.6)

14 (30.4)

 

Marital status, n (%)

     

0.277

 Single

33 (15.7)

2 (7.1)

13 (15.3)

10 (19.6)

8 (17.4)

 

 Married or cohabiting

110 (52.4)

18 (64.3)

48 (56.5)

25 (49.0)

19 (41.3)

 

 Others

67 (31.9)

8 (28.6)

24 (28.3)

16 (31.4)

19 (41.3)

 

Employment, n (%)

     

0.217

 Employed

51 (24.3)

9 (32.1)

19 (22.4)

14 (27.5)

9 (19.6)

 

 Unemployed

33 (15.7)

6 (21.4)

8 (9.4)

11 (21.6)

8 (17.4)

 

 Freelancer

86 (41.0)

11 (39.3)

42 (49.4)

16 (31.4)

17 (37)

 

 Retired

40 (19.0)

2 (7.1)

16 (18.8)

10 (19.6)

12 (26.1)

 

Family income, n (%)

     

0.746

  < 3000 RMB

92 (43.8)

16 (57.1)

35 (41.2)

19 (37.3)

22 (47.8)

 

 3000–6000 RMB

83 (39.5)

9 (32.1)

36 (42.3)

22 (43.1)

16 (34.8)

 

  > 6000 RMB

35 (16.7)

3 (10.8)

14 (16.5)

10 (19.6)

8 (17.4)

 

Region, n (%)

     

0.156

 Urban

112 (53.3)

11 (39.3)

46 (54.1)

25 (49.0)

30 (65.2)

 

 Rural

98 (46.7)

17 (60.7)

39 (45.9)

26 (51.0)

16 (34.8)

 

Stage of disease, n (%)

     

0.002

 Acute stage

5 ( 2.4)

3 (10.7)

0 (0.0)

1 (2.0)

1 (2.2)

 

 Asymptomatic stage

143 (68.1)

15 (53.6)

62 (72.9)

42 (82.4)

24 (52.2)

 

 AIDS stage

62 (29.5)

10 (35.7)

23 (27.1)

8 (15.7)

21 (45.7)

 

CD4+T cell count, n (%)

     

0.004

  < 200

40 (19.0)

10 (35.7)

19 (22.4)

7 (13.7)

4 (8.7)

 

 200–499

83 (39.5)

15 (53.6)

33 (38.8)

19 (37.3)

16 (34.8)

 

  ≥ 500

87 (41.4)

3 (10.7)

33 (38.8)

25 (49.0)

26 (56.5)

 

Comorbidities, n (%)

     

0.143

 No

171 (81.4)

23 (82.1)

73 (85.9)

36 (70.6)

39 (84.8)

 

 Yes

39 (18.6)

5 (17.9)

12 (14.1)

15 (29.4)

7 (15.2)

 

 PHSD, Median (IQR)

0.1 (0.0, 0.4)

0.1 (0.0, 0.3)

0.0 (0.0, 0.2)

0.3 (0.0, 0.8)

0.2 (0.0, 0.4)

 < 0.001

 COSD, Median (IQR)

0.0 (0.0, 0.4)

0.0 (0.0, 0.0)

0.0 (0.0, 0.2)

0.0 (0.0, 0.7)

0.0 (0.0, 0.6)

0.022

 PSYSD, Median (IQR)

0.0 (0.0, 0.2)

0.0 (0.0, 0.2)

0.0 (0.0, 0.0)

0.0 (0.0, 0.5)

0.0 (0.0, 0.0)

0.010

 Total.Score, Median (IQR)

0.1 (0.0, 0.9)

0.2 (0.0, 0.6)

0.0 (0.0, 0.5)

0.5 (0.0, 2.0)

0.3 (0.0, 1.2)

 < 0.001

  1. PHSD Physical Symptom Distress, COSD Cognitive Symptom Distress, PSYSD Psychological Symptom Distress